dr darshit shah | nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced rcc
Published 1 year ago • 226 plays • Length 10:14Download video MP4
Download video MP3
Similar videos
-
1:56
checkmate 9er: arcc patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib
-
8:04
dr m v chandrakanth | cabozantinib is the preferred 1st line in advanced renal cell carcinoma
-
4:19
nivolumab plus cabozantinib for patients with advanced rcc with sarcomatoid histology
-
1:06
dr. toni choueiri on nivolumab and cabozantinib becoming first-line therapies in rcc
-
3:35
checkmate-9er discussion: depth of response with first-line cabozantinib/nivolumab
-
1:38
kidney cancer research at esmo 2020: toni choueiri, md
-
1:44
dr. choueiri on cabosun trial results in rcc
-
5:31
newly diagnosed metastatic renal cell carcinoma
-
1:37
dr. shuch on caveats of avelumab/axitinib combination in rcc
-
6:06
the combination of sitravatinib and nivolumab for the treatment of advanced clear cell renal cel...
-
6:52
nivolumab in renal cell carcinoma
-
1:06
dr. choueiri on fda approval of cabozantinib for rcc
-
1:47
dr. choueiri discusses avelumab/axitinib data in rcc
-
13:25
who is your ideal sunitinib patient? camillo porta, m.d.
-
1:24
dr. figlin on sunitinib for patients with rcc
-
2:32
dr. motzer on sunitinib versus pazopanib in renal cell carcinoma
-
4:43
nivolumab in renal cell carcinoma
-
1:05:38
watch drs. choueiri, mcdermott, and tannir, discuss the latest in rcc: https://bit.ly/3n3x59m